Orion (ORNBV) Q4 2024 earnings summary

Executive summary

• Net sales rose 29.6% year-over-year to EUR 1,542.4 million, with operating profit up 51.5% to EUR 416.6 million, driven by strong growth in Innovative Medicines, especially Nubeqa® and milestone payments.

• Nubeqa® sales and royalties exceeded EUR 1 billion in September 2024, achieving blockbuster status and driving growth across four of five business divisions.

• The company reached its EUR 1.5 billion net sales target ahead of schedule and expanded its geographic footprint, including a new sales office in Japan.

• Major R&D investments, new and expanded partnerships, and licensing agreements supported both short- and long-term growth.

• Management changes included new CFO, SVP People and Culture, and General Counsel appointments.

Financial highlights

• Q4 2024 net sales grew 35.3% year-over-year to EUR 434.4 million; operating profit stable at EUR 92.7 million.

• Full-year operating profit margin improved to 27.0% from 23.1% in 2023; basic EPS EUR 2.35 (+52.0%).

• Underlying net sales up 21.8% and underlying operating profit up 32.2% year-over-year.

• Major write-downs: EUR 17.5 million (ODM-111 termination) and EUR 23.5 million (ganaxolone contract termination), totaling EUR 41 million.

• Cash flow from operating activities per share more than doubled to EUR 2.09; cash flow improved from previous year.

Outlook and guidance

• 2025 net sales guidance: EUR 1,550–1,650 million; operating profit guidance: EUR 350–450 million.

• Outlook excludes material milestone payments; assumes continued growth in Nubeqa® royalties and product sales.

• Growth of Nubeqa® is the most significant variable; wider guidance range reflects uncertainty in R&D timing and FX rates.

• R&D costs expected to increase; sales and marketing expenses to remain similar, with growth in Easyhaler® and Japan.